Publication
Title
Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)
Author
Abstract
Background This phase II study was conducted to determine the antitumour activity of gemcitabine in adenoid cystic carcinoma (ACC). Patients and methods Patients with progressive and/or symptomatic, recurrent and/or metastatic ACC were treated with gemcitabine 1250 mg/m2 intravenous (i.v.) on days 1 and 8 of each 21-day cycle. Each cycle was repeated every 3 weeks in the absence of disease progression for a minimum of four cycles and a maximum of 12 cycles. Results Among 21 ACC patients, there were no objective responses. Eleven patients had a stable disease, of which ten patients for more than 6 months, and eight had a progressive disease after 4 cycles. Gemcitabine was well tolerated by most patients. Conclusion We conclude that gemcitabine is not an active drug in ACC.
Language
English
Source (journal)
European journal of cancer. - Oxford, 1990, currens
Publication
Oxford : 2008
ISSN
0959-8049
Volume/pages
44:17(2008), p. 2542-2545
ISI
000261562700009
Full text (Publishers DOI)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identification
Creation 24.11.2008
Last edited 15.05.2017
To cite this reference